Provided herein are methods and constructs related to minimizing immune responses using modified dexamethasone compounds when administering a desired transgene in a cell achieved by delivery of the transgene with one or more doses of a ceDNA construct.

Provided herein are compositions and methods for delivering non-viral, capsid-free DNA vectors (ceDNA) to cytosol of a target cell in subject while reducing or inhibiting an immune response.

Methods of determining the stoichiometry of a viral capsid and/or determining the heterogeneity of protein components in a viral capsid are disclosed.

The present invention relates to insect cell lines for the production of parvoviral gene therapy vectors. In particular the invention relates to stable insect cell lines with expression constructs for viral replicase proteins integrated into their genomes, which cell lines allow for high-yield, robust, and scalable production of heterologous parvoviral-related proteins and vectors.

A prophylactic and/or therapeutic food composition for control of deformed wing vims (DWV) in bees and/or bee larvae, and methods of using and making the same. Bee feed compositions comprising anti-DWV antibodies dispersed in an edible base composition. Use of recombinant VP1, VP2, VP3, and/or VP4 capsid proteins, or VLPs of deformed wing vims (DWV) to passively generate anti-DWV antibodies in chicken egg yolks, and use of such anti-DWV antibodies for prophylaxis or treatment of deformed wing virus in the bees and/or larvae.

The present disclosure describes methods and systems for use in the production of recombinant adeno-associated virus (rAAV) particles comprising a payload (e.g., a polynucleotide encoding aromatic L-amino acid decarboxylase (AADC) or a functional variant thereof). In certain embodiments, the production process uses Sf9 insect cells as viral production cells. In certain embodiments, the production process and system use Baculoviral Expression Vectors (BEVs) and/or Baculoviral Infected Insect Cells (BIICs) in the production of rAAV particles.

Disclosed herein are compositions comprising recombinant adeno-associated virus (rAAV), as well as recombinant baculovirus systems and methods of using the same for producing and purifying such compositions. Also disclosed herein are assays for testing the titer and potency of such compositions.

The present invention relates to production of proteins in insect cells whereby repeated coding sequences are used in baculoviral vectors. In particular the invention relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral rep proteins that increase the productivity of parvoviral vectors.

An immunogenic composition, a SARS-CoV-2 vaccine and a vector are introduced. The immunogenic composition has a recombinant protein having a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and any polypeptide encoded by a polynucleotide which is at least 80% homologous with SEQ ID NO: 1-4, wherein the recombinant protein contains an IgG1 Fc protein fragment having a length of at least 6 amino acids; or a nucleic acid molecule encoding the recombinant protein. The SARS-CoV-2 vaccine has the above recombinant protein or the nucleic acid molecule encoding the above recombinant protein. The vector has the nucleic acid molecule encoding the above recombinant protein.

The present disclosure describes methods and systems for use in the production of adeno-associated virus (AAV) particles, including recombinant adeno-associated virus (rAAV) particles. In certain embodiments, the production process and system use Spodoptera frugiperda insect cells (such as Sf9 or Sf21) as viral production cells. In certain embodiments, the production process and system use Baculoviral Expression Vectors (BEVs) in the production of AAV particles. In certain embodiments, the production process and system uses an engineered nucleic acid construct which encodes for AAV capsid proteins, such as VP1, VP2 and VP3. In certain embodiments, the production process and system uses an engineered nucleic acid construct which encodes for AAV replication proteins, such as Rep78 and Rep52.